Tetracaine is an amino-ester class local anesthetic, primarily used for short-term procedures on the surface of the eye, as well as in the ears and nose. It is also employed for spinal anesthesia. Its affordability and inclusion on the World Health Organization's (WHO) list of essential medications highlight its value in medical practice. Tetracaine is typically administered topically or via intrathecal injection, with dosing dependent on the area of application and type of procedure.
The mechanism of action of tetracaine involves blocking intracellular sodium channels, preventing sodium influx, and halting nerve signal transmission. It acts more effectively on nerves that are already active due to its binding preference for sodium channels in the open-activated state. The drug's high lipid solubility and moderate protein binding contribute to its potency and duration of action.
While generally safe, tetracaine carries risks of adverse effects, particularly central nervous system toxicity, which may manifest as dizziness, blurry vision, and seizures. In severe cases, cardiac complications such as arrhythmias or bradycardia may occur. Allergic reactions, though rare, are more common with ester-type anesthetics like tetracaine, especially due to the metabolite para-aminobenzoic acid (PABA). Contraindications include prior severe allergic responses, and caution is advised in patients with liver disease or pseudocholinesterase deficiency.
To minimize risk, it is important to monitor patients closely during administration, particularly with regard to ECG, pulse oximetry, and blood pressure. The use of vasoconstrictors can help slow absorption in high-vascularity areas, reducing the potential for systemic toxicity. Tetracaine remains an effective and widely used anesthetic when managed properly within a coordinated interprofessional care team.
